University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Most patients who reach disease remission following anti-TNF therapy continue to report fatigue : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Simple item page
dc.contributor.authorDruce, Katie L.
dc.contributor.authorBhattacharya, Yagnaseni
dc.contributor.authorJones, Gareth T.
dc.contributor.authorMacfarlane, Gary J.
dc.contributor.authorBasu, Neil
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Epidemiology Groupen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Arthritis and Musculoskeletal Health (ACAMH)en
dc.contributor.institutionUniversity of Aberdeen.Grampian Data Safe Haven (DaSH)en
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2017-06-21T23:03:12Z
dc.date.available2017-06-21T23:03:12Z
dc.date.embargoedUntil2017-06-21
dc.date.issued2016-10
dc.descriptionAcknowledgements K.L.D. was funded by a studentship from the Institute of Applied Health Sciences, University of Aberdeen. Y.B. was funded by a studentship from the Aberdeen Summer Research Studentship Programme, University of Aberdeen. The BSR commissioned the BSRBR-RA as a UK-wide national project to investigate the safety of biologic agents in routine medical practice. BSR receives restricted income from UK pharmaceutical companies, including Abbott Laboratories, Merck, Pfizer, Roche, UCB and SOBI. This income finances a wholly separate contract between the BSR and the University of Manchester, who provide and oversee the BSRBR-RA data collection, management and analysis service. The principal investigators and their team have full academic freedom and are able to work independently of pharmaceutical industry influence. All decisions concerning analyses, interpretation and publication are made autonomously of any industry contributions. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. Disclosure statement: The authors have declared no conflicts of interest.en
dc.description.statusPeer revieweden
dc.format.extent5
dc.format.extent52948
dc.identifier68783315
dc.identifier330b8d6b-7178-43ec-8ffd-2dcddf1e5109
dc.identifier84991058648
dc.identifier.citationDruce, K L, Bhattacharya, Y, Jones, G T, Macfarlane, G J & Basu, N 2016, 'Most patients who reach disease remission following anti-TNF therapy continue to report fatigue : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis', Rheumatology, vol. 55, no. 10, pp. 1786-1790. https://doi.org/10.1093/rheumatology/kew241en
dc.identifier.doi10.1093/rheumatology/kew241
dc.identifier.iss10en
dc.identifier.issn1462-0324
dc.identifier.otherORCID: /0000-0003-2322-3314/work/29064667
dc.identifier.otherORCID: /0000-0003-0016-7591/work/83703948
dc.identifier.urihttp://hdl.handle.net/2164/8848
dc.identifier.vol55en
dc.language.isoeng
dc.relation.ispartofRheumatologyen
dc.subjectfatigueen
dc.subjectdisease activityen
dc.subjectremissionen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleMost patients who reach disease remission following anti-TNF therapy continue to report fatigue : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritisen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Yagna_manuscript_1_.docx
Size:
51.71 KB
Format:
Unknown data format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
8.29 KB
Format:
Plain Text
Description:
Download

Collections

All research
Applied Health Sciences research
University Office research